Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 8155326 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Stephens RM, et al. (1994) Trk receptors use redundant signal transduction pathways involving SHC and PLC-gamma 1 to mediate NGF responses. Neuron 12, 691-705 8155326
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

Y204-p - ERK1 (human) ▲
Orthologous residues
ERK1 (human): Y204‑p, ERK1 (mouse): Y205‑p, ERK1 (rat): Y205‑p, ERK1 (hamster): Y194‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase

Y187-p - ERK2 (human) ▲
Orthologous residues
ERK2 (human): Y187‑p, ERK2 (mouse): Y185‑p, ERK2 (rat): Y185‑p, ERK2 (chicken): Y195‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase

Y496-p - TrkA (human) ▲
Orthologous residues
TrkA (human): Y496‑p, TrkA iso2 (human): Y490‑p, TrkA (mouse): Y499‑p, TrkA (rat): Y499‑p, TrkA iso2 (rat): Y493‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE TrkA (human)
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, molecular association, regulation
 Effect of modification (process):  cell growth, altered
 Modification regulates interactions with: 
Interacting molecule Interacting domains Effect Consequences (function) Consequences (process) Detection assays
Shc1 (human) Induces molecular association, regulation, phosphorylation co-immunoprecipitation, in vitro
 Comments:  association in vitro and in vivo; regulate NGF induced neurite outgrowth and ERK activity

Y680-p - TrkA (human) ▲
Orthologous residues
TrkA (human): Y680‑p, TrkA iso2 (human): Y674‑p, TrkA (mouse): Y683‑p, TrkA (rat): Y683‑p, TrkA iso2 (rat): Y677‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE TrkA (human)

Y681-p - TrkA (human) ▲
Orthologous residues
TrkA (human): Y681‑p, TrkA iso2 (human): Y675‑p, TrkA (mouse): Y684‑p, TrkA (rat): Y684‑p, TrkA iso2 (rat): Y678‑p
Characterization
 Enzymes shown to modify site in vitro: 
Type Enzyme
KINASE TrkA (human)

Y791-p - TrkA (human) ▲
Orthologous residues
TrkA (human): Y791‑p, TrkA iso2 (human): Y785‑p, TrkA (mouse): Y794‑p, TrkA (rat): Y794‑p, TrkA iso2 (rat): Y788‑p
Characterization
 Methods used to characterize site in vivo:  phospho-antibody, western blotting
 Disease tissue studied:  adrenal cancer, pheochromocytoma
 Relevant cell lines - cell types - tissues:  PC-12 (chromaffin)
 Cellular systems studied:  cell lines
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
NGF increase
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced
 Effect of modification (process):  cell growth, altered
 Comments:  regulate NGF induced neurite outgrowth and ERK activity


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.